Search Results
Your search for The,The matches 34480 pages
Showing 1 - 50Novel Limonene-Lipid Formulation May Help Alleviate Xerostomia in Patients With Cancer
When combined with a novel lipid formulation, a natural citrus essential oil from oranges, lemons, and limes—known as limonene—may prove to be effective in relieving xerostomia without significant adverse effects among patients with cancer, according to a recent study published by Wright et al in...
Prevalence of Genetic Testing in Women With Ovarian Cancer
Investigators have found that nearly 50% of women diagnosed with ovarian cancer may not be receiving the genetic testing that could help guide their treatment and potentially improve outcomes, according to a recent report conducted by the Ovarian Cancer Research Alliance (OCRA) and Komodo Health....
Early-Stage NSCLC: Geographic Access to Cancer Care and Outcomes
In a study reported in JAMA Network Open, Shrestha et al found that receipt of recommended care and treatment outcomes were associated with geographic access to care in U.S. patients with early-stage non–small cell lung cancer (NSCLC). Study Details The study involved data from the Surveillance,...
Age, ET Persistence, and Disease-Free Survival in HR-Positive Early Breast Cancer
In a French study reported in the Journal of Clinical Oncology, Dumas et al found that improved endocrine therapy (ET) persistence among young patients with hormone receptor (HR)-positive early breast cancer would likely lead to improved disease-free survival. Study Details The study used data from ...
Interventions to Improve Uptake of FIT Colorectal Cancer Screening in Scotland
In a Scottish study (TEMPO) reported in The Lancet, Robb et al found that a behavioral intervention adding a deadline for fecal immunochemical testing (FIT) return in the invitation letter to FIT colorectal cancer screening resulted in superior uptake of testing. Study Details In the trial, 40,000...
Adjuvant Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
In a study reported in JAMA Oncology, Agusti et al found that the addition of chemotherapy to adjuvant radiotherapy was not associated with improved overall survival in patients with intermediate-risk cervical cancer. Study Details The study involved National Cancer Database data on patients with a ...
Building and Sharing Dietary Evidence in Cancer Care
Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...
Enfortumab Vedotin–Based Approaches to Metastatic Urothelial Carcinoma
In a systematic review and meta-analysis reported in JAMA Network Open, Yajima et al found that both pembrolizumab plus enfortumab vedotin-ejfv and enfortumab vedotin alone were active in the first-line setting and later lines of therapy, respectively, in metastatic urothelial carcinoma. Study...
Lifetime Body Weight Patterns Could Affect Risk of Developing Renal Cell Carcinoma
Weight patterns throughout life may affect an individual’s likelihood of developing renal cell carcinoma, according to a recent study published by Deng et al in Cancer. Study Methods and Results In the study, investigators used data from the NIH-AARP Diet and Health Study to assess weight patterns...
Delays in Breast Cancer Surgery Could Raise Mortality Risk for Certain Subtypes
Waiting more than 42 days postdiagnosis to undergo surgery could increase the risk of cancer-related mortality among patients with certain breast cancer subtypes, according to a recent study published by Salewon et al in Breast Cancer Research. Background Hormone receptor–positive and HER2-negative ...
FDA Approves Cabozantinib for pNET and epNET
Today, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...
Are New-Onset Type 2 Diabetes and Obesity-Related Cancers Linked?
A new diagnosis of type 2 diabetes may be linked to a subsequent increased risk of developing some obesity-related cancers, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Previous research has uncovered associations between type 2 diabetes and a...
Hypofractionated Radiotherapy in Prostate Cancer
In an individual patient data meta-analysis reported in The Lancet Oncology, Kishan et al found that isodose and dose-escalated moderately hypofractionated radiotherapy exhibited similar efficacy vs conventionally fractionated radiotherapy in patients with localized prostate cancer. They also...
Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?
Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced...
Sex Differences in Waist Circumference vs BMI as Risk Factors for Obesity-Related Cancers
Waist circumference may be a more effective risk marker for the development of obesity-related cancers than body mass index (BMI) in male but not female patients, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Body size and excess...
HER2-Selective TKI in Advanced Solid Tumors with HER2 Alterations
In a phase Ia/Ib study (Beamion LUNG-1) reported in the Journal of Clinical Oncology, Heymach et al evaluated the safety profile and activity of zongertinib in patients with HER2-altered solid tumors. Zongertinib is a novel HER2-selective tyrosine kinase inhibitor (TKI) that spares EGFR, thereby...
Microultrasound- vs MRI-Guided Biopsy for Prostate Cancer Diagnosis
Biopsies guided by high-resolution ultrasound may be as effective as those using magnetic resonance imaging (MRI) in diagnosing prostate cancer, an international clinical trial has shown. The technology, called micro-ultrasound, is cheaper and easier to use than MRI. It could significantly speed up ...
Case 3: Progression of HR-Positive/HER2-Negative Metastatic Breast Cancer After Adjuvant CDK4/6 Inhibition
This is Part 3 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss the treatment of...
Case 2: Progression After First-Line CDK4/6 Inhibitors in ER-Positive Metastatic Breast Cancer
This is Part 2 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss how to approach the...
Case 1: First-Line Therapy in HR-Positive Metastatic Breast Cancer
This is Part 1 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss the first-line...
TB Vaccination Could Enhance BCG Response in Patients With Non–Muscle-Invasive Bladder Cancer, Study Finds
Two doses of a simple tuberculosis (TB) vaccination after surgery helps the immune system fight cancer cells and may improve patient outcomes among those with non–muscle-invasive bladder cancer, according to a pilot study of 40 patients. Initial results from the RUTIVAC-1 Trial were presented by...
Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?
A simple urine test could accurately detect clear cell renal cell carcinoma (RCC) recurrence at an early stage, potentially sparing patients from undergoing invasive scans and enabling quicker access to treatment, according to new findings presented by Dabestani et al at the European Association of ...
Novel Strategy Could Help Recover Erectile Function Following Prostate Cancer Surgery
A novel technique designed to improve the precision of prostate cancer surgery could preserve erectile function in nearly twice as many men compared with standard surgery, according to new findings presented by Almeida-Magana et al at the European Association of Urology (EAU) Congress 2025...
Conundrums in Treating HER2-Positive Early Breast Cancer
Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...
Virtual Reality Therapy May Improve Chemotherapy-Associated Side Effects
A study conducted by Stansel et al, which was published in the journal Clinical Journal of Oncology Nursing, highlighted the potential of virtual reality therapy to reduce patient stress, pain, and negative affect during chemotherapy sessions. The findings also appeared to support its delivery and...
New Reports Assess Oncology Workforce Well-Being, Propose Solutions to Address Burnout
Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...
Results Announced From Phase II VERITAC-2 Clinical Trial in Breast Cancer
Arvinas, Inc. and Pfizer Inc. recently announced results from the randomized phase III VERITAC-2 clinical trial (ClinicalTrials.gov identifier NCT05654623) evaluating vepdegestrant monotherapy vs fulvestrant in adults with estrogen receptor–positive, HER2-negative advanced or metastatic breast...
Screening Was Key to the Early Detection of My Prostate Cancer
As a Native American and former president of the Seneca Nation of Indians, I am keenly aware of the disparities in cancer care we face in accessing screening and treatment, which results in worse survival rates compared with those of racial and ethnic populations.1 Native American and Alaska Native ...
CMS Expects Between 750,000 to 2 Million to Lose Coverage If ACA Proposal Is Implemented
On March 10, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Marketplace Integrity and Affordability Proposed Rule aimed at addressing improper enrollments in the Affordable Care Act (ACA) Health Insurance Marketplace. This is the first proposed rule released under the new ...
Bringing Palliative Care to Every Patient With Cancer
Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.” —Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Benefit Suggested for Early Treatment of Advanced-Stage, Very Low–Tumor Burden Follicular Lymphoma
In the phase III JCOG1411/FLORA trial of patients with untreated advanced-stage, very low–tumor burden follicular lymphoma, rituximab induction delayed disease progression to high–tumor burden follicular lymphoma and delayed the initiation of cytotoxic chemotherapy, according to Japanese...
Conexiant Signs Partnership Deal With Elsevier to Enhance Society Marketing and Member Engagement Solutions
Conexiant has partnered with Elsevier to deliver world-class solutions and sales execution to more than 100 global societies and associations covering more than 25 core specialties in the health-care space. This collaboration marks a significant step forward in delivering innovative advertising,...
Case 3: Unresectable EGFR-Mutant NSCLC
This is Part 3 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of unresectable...
Case 2: Resectable EGFR-Mutant NSCLC
This is Part 2 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of resectable EGFR-mutant...
Case 1: Resected EGFR-Mutant NSCLC
This is Part 1 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of resected EGFR-mutant...
Confronting the Growing Global Threat of Antimicrobial Resistance in Cancer Care
The dire warnings about the lethal consequences of unchecked antimicrobial resistance are getting louder and becoming more urgent. The U.S. Department of Health and Human Services has called antimicrobial resistance “one of the most important health security threats of our time,” with at least 2.8...
New Guideline Supports Transoral Robotic Surgery in the Multidisciplinary Management of Patients With Oropharyngeal Cancer
Transoral robotic surgery (TORS) can offer patients with oropharyngeal squamous cell carcinoma (OPSCC) improved survival while minimizing or avoiding late toxicities associated with the standard of care of radiation with cisplatin chemotherapy, according to a recent ASCO guideline.1 “We show in a...
New ASCO Guideline Addresses Germline and Somatic Genomic Testing in Metastatic Prostate Cancer
Prostate carcinoma is the most common type of cancer among men in the United States, accounting for more than 299,000 estimated new cases and approximately 35,000 new deaths in 2024.1 A new ASCO guideline based on findings from a systematic review indicates that in metastatic cases of prostate...
Early Research Evaluates Association Between Diet and Lung Cancer Risk
The long-term impact of diet on health has been well studied, leading to guidance about limiting the consumption of red meat, alcohol, and other foods associated with an increased risk of malignancies such as colorectal, breast, and liver cancers. Researchers at the University of Florida Health...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
High Levels of PTSD May Exist Among Caregivers of Adult Patients With Cancer
Investigators looked into the toll that caregiving for adult patients with cancer may take on the mental health of caregivers, according to a recent study published by Klekovkina et al in Archives of Gerontology and Geriatrics Plus. Background Millions of family members and friends provide care for ...
Colorectal Cancer May Be Linked to Heightened Risk of Cardiovascular Mortality
The risk of death from cardiovascular causes may be higher among patients diagnosed with colorectal cancer compared with the general population, according to new findings presented by Ayaz et al at the American College of Cardiology (ACC) Annual Scientific Session 2025. Background Cardiovascular...
Can Adding Antihistamines to Second-Line Therapy Improve Outcomes in Advanced Urothelial Carcinoma?
As reported in the journal Urologic Oncology: Seminars and Original Investigations by Fallara et al, an analysis of individual patient data from the IMvigor210 and IMvigor211 trials revealed that concomitant second-line treatment of locally advanced or metastatic urothelial carcinoma with...
Advanced Refractory Melanoma: Addition of Tilsotolimod to Ipilimumab
As reported in the Journal of Clinical Oncology by Adi Diab, MD, and colleagues, the phase III ILLUMINATE trial showed adding the Toll-like receptor-9 agonist tilsotolimod to ipilimumab in patients with advanced refractory melanoma produced no benefit. Study Details Four hundred and eighty-one...
Benefit of Regular Physical Activity Prior to Cancer Diagnosis
Regular physical activity prior to a cancer diagnosis may be linked to a lower risk of disease progression and mortality, according to a recent study conducted by Professor Jon S. Patricios, MBBCh, of the University of Witwatersrand, Johannesburg, South Africa, and colleagues and published in the...
Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO...
Douglas Hanahan, PhD, FAACR, to Be Honored at 2025 AACR Annual Meeting
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas Hanahan, PhD, FAACR, during the upcoming 2025 AACR Annual Meeting, to be held April 25–30 at the McCormick Place Convention...
Monica M. Bertagnolli, MD, FACS, FASCO, Joins Friends of Cancer Research Board of Directors
Friends of Cancer Research (Friends) is honored to announce the addition of former Director of the National Institutes of Health (NIH) Monica M. Bertagnolli, MD, FACS, FASCO, to its Board of Directors. “Dr. Bertagnolli has built her incredible career around improving the lives of patients through...
Recent FDA Approvals in Lymphoma and in Rarer Tumors
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising ...
